Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Figure 1: Percentage change in the number of people dying from AIDS-related causes between 2005 and 2011 in countries with 100 or more AIDS-related deaths.

Advertisements

Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy.

Costs and Expected Benefits of Investment in Cervical Cancer Prevention Nicole G. Campos, PhD.

HSV-1/HSV-2 Infection-Related Cancers in Bantu Populations Driving HIV-1 Prevalence in Africa: Tracking the Origin of AIDS at the Onset of the 20th Century.

Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia:

Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis Dr Laia Bruni, MD, Mireia Diaz, PhD, Leslie.

Viral infections and cancer

Figure 1 Estimated annual percentages of new

Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis Dr Laia Bruni, MD, Mireia Diaz, PhD, Leslie.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Life expectancy at birth in all countries included

Progress and Challenges with achieving Universal Immunization Coverage

Nasreen Abdullah, MD, MPH

Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study Alejandra Castanon, MD, Rebecca Landy, PhD,

Figure 2 Multiscale modelling in oncology

The Lancet Public Health

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus T. Bärnighausen, D.E. Bloom, E.T. Cafiero,

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Cervical cancer incidence can increase despite HPV vaccination

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

HPV vaccination crisis in Japan

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 3 Cell-surface markers for NP cell differentiation

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from.

Preventing HPV-related Disease: What Do the Latest Data Tell Us?

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia:

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study Mark Jit, PhD, Marc Brisson, PhD, Allison Portnoy,

Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study Helen C Johnson, MSc, Erin I Lafferty, PhD, Rosalind.

Figure 2 Frequency and overlap of alterations

Accelerating cervical cancer control and prevention

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Figure 7 Prototypes of topological mechanical metamaterials

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

HPV vaccination crisis in Japan

Figure 1 Gene-expression quantification methods

Fig. 5 Comparison of the liquid products generated from photocatalytic CO2 reduction reactions (CO2RR) and CO reduction reactions (CORR) on two catalysts.

Lung cancer incidence for men and women in Sweden and Norway from 1960–1999 for age standardised rates per inhabitants based upon census population.

Fig. 2 Time series of secularization versus GDP per capita, from four illustrative countries, over the 20th century. Time series of secularization versus.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.146 Figure 3 Modelling the effects of increasing the number of age cohorts vaccinated against HPV16/18 on time to reduction in the prevalence of HPV infection Figure 3 | Modelling the effects of increasing the number of age cohorts vaccinated against HPV16/18 on time to reduction in the prevalence of HPV infection. Baussano et al.131 assessed the effectiveness of HPV16/18 vaccination, in terms of prevention of cervical HPV16/18 infections, among women aged ≤35 years, with catch-up vaccination of women aged 17–24 years. Using a mathematical model of HPV16/18 transmission and information on vaccination coverage among 11-year-old girls in an Italian population (65% coverage), the data were calculated based on the assumption of 50% vaccination coverage within the catch-up cohorts. Data were modelled for catch-up vaccination of women in four age groups, comprising between two and eight 1-year birth cohorts. Catch-up vaccination of an age group that spanned eight consecutive 1-year birth cohorts, encompassing women aged 17–24 years, was estimated to move forward by 2 years the time at which 50% vaccine effectiveness against HPV16/18 infection would be reached in the population. Abbreviation: HPV16/18, human papillomavirus types 16 and 18. Figure adapted from Baussano, I. et al. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect. Agent. Cancer 9, 4 http://dx.doi.org/10.1186/1750-9378-9-4 (2014); © 2014 Baussano et al.; licensee BioMed Central Ltd, which was published under a Creative Commons Attribution License 2.0 Generic (CC BY 2.0; http://creativecommons.org/licenses/by/2.0/) Figure adapted from Baussano, I. et al. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect. Agent. Cancer 9, 4 http://dx.doi.org/10.1186/1750-9378-9-4 (2014); © 2014 Baussano et al.; licensee BioMed Central Ltd, which was published under a Creative Commons Attribution License 2.0 Generic (CC BY 2.0; http://creativecommons.org/licenses/by/2.0/) Bosch, F. X. et al. (2015) HPV-FASTER: broadening the scope for prevention of HPV-related cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.146